#Wearable #MedicalDevices Snapshot - (OTC: $GTCHD) (NYSE: $SENS) (Nasdaq: $GRMN) (Nasdaq: $DXCM) (Nasdaq: $GOOG) @senseonics @Garmin @Google; #artificialintelligence

 

 

#Wearable #MedicalDevices Snapshot - (OTC: $GTCHD) (NYSE: $SENS) (Nasdaq: $GRMN) (Nasdaq: $DXCM) (Nasdaq: $GOOG) @senseonics @Garmin @Google; #artificialintelligence

 

Point Roberts WA, Vancouver BC–October 27,  2021  – Investorideas.com (https://www.investorideas.com/), a global investor news source covering Artificial Intelligence (AI) issues a sector snapshot looking at the wearable medical device market, featuring technology company GBT Technologies Inc. (OTCPINK:GTCHD).  

 

Read this article, featuring GTCHD in full at https://www.investorideas.com/news/2021/artificial-intelligence/10271GTCHD-SENS-GRMN-DXCM-GOOG.asp

 

With ongoing developments in areas such as Internet of things (IoT) and Artificial Intelligence (AI), and given the backdrop of the COVID-19 pandemic, the demand for mobile or wearable medical devices is, understandably, on the rise. In fact, research published by Coherent Market Insights finds that the global wearable medical devices market, which was valued at approximately $29.83 billion USD in 2020, is projected to reach $50.89 billion by the end of 2027. This category encompasses wearable therapeutic devices, wearable monitoring and diagnostic devices, and health and fitness devices. And it’s not only, or even mainly, COVID-19 driving demand. According to the report’s summary, demand for wearable medical devices is expected to be driven by a “high prevalence of chronic diseases,” and an “increasing geriatric population.”

 

One company that recently announced plans for this space is GBT Technologies Inc. (OTC PINK:GTCHD). GBT, an early stage technology developer in (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms is now roadmapping a wearable version of its qTerm human vitals device. The current finger-touch version of the qTerm measures a user’s body temperature, blood oxygen level and heart rate. Danny Rittman, the company’s CTO, explained:

 

"It is only natural to create a wearable version of qTerm technology. One of the major advantages of a wearable form of qTerm is its capabilities to take health related measurements; independently, and without the user's awareness, this feature can be enabled upon the user's permission. We see this feature as a great advantage; especially, when users may forget to take their scheduled vitals, not aware of a potential problem. The wearable version of qTerm will be equipped with the same AI system for on-going health monitoring, and it will learn about a user's health condition and perform scheduled checks to ensure good health. These checks will be executed throughout the day or night and in case of abnormalities the user will be alerted, and can be an efficient health monitoring system for the elderly; 24/7. In qTerm's finger-touch version the responsibility to perform a vitals check lies on the user remembering to take these on time. However, with the wearable device the checks will be automatically executed throughout the day in case the user forgets their daily health-related duties, this system will do it for them. qTerm wearable will include a website synchronized mobile application for results representation. This advanced mobile application will make the qTerm wearable device a personal health monitoring system constantly on the watch, checking, analyzing and advising/alerting about any health concerns.”

 

Chronic diseases were cited as key drivers of the wearable medical device market by the aforementioned Coherent Market Insights report, and one such chronic disease is diabetes. Medical technology company Senseonics Holdings, Inc. (NYSEAmerican:SENS), which focuses on the development and commercialization of the long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, and Ascensia Diabetes Care, the makers of the CONTOUR family of diabetes blood glucose monitoring devices and commercialization partner for Senseonics, recently announced that the University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio has begun offering the Eversense CGM System to its Medicare enrollees effective early September, 2021. According to the press release, the Eversense CGM System “consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts.” Betul Hatipoglu, M.D., Head of Endocrinology and Diabetes at UHACO, commented:

 

"We are excited to offer Eversense to our ACO patients with diabetes. Supplying tools for effective glucose management allows us to meet the Standards of Care for patients using insulin as outlined by the American Diabetes Association. Eversense offers patients choice amongst continuous glucose monitoring devices. The Eversense CGM system delivers industry leading accuracy, an improved patient experience, and an array of unique features that afford people, especially those in the Medicare population, the opportunity to achieve improved health outcomes."

 

Similarly, Garmin International, Inc., a unit of multinational tech firm Garmin Ltd. (NasdaqGS:GRMN), recently introduced the Dexcom Connect IQ apps, “providing people with Type 1 and Type 2 diabetes who use the Dexcom^® G6 Continuous Glucose Monitor (CGM) System¹ with a way to quickly see their glucose levels and trends – even while working out – right on their compatible Garmin smartwatch or cycling computer.” Jake Leach, CTO at Dexcom (NasdaqGS:DXCM), said:

 

"The addition of Garmin wearables and cycling computers to the Dexcom CGM ecosystem is an exciting advancement for Dexcom users who are now able to easily view and monitor their glucose levels from their favorite Garmin device. Garmin is our first partner to connect to Dexcom G6 through our new real-time API – showcasing the value of integrated CGM and further solidifying Dexcom G6 as the most powerful and connected CGM in the world."

 

Recently Onduo, part of life sciences research organization Verily, an independent subsidiary of Alphabet Inc. (NasdaqGS:GOOG), recently announced that it “will offer Fitbit devices and Fitbit Premium as part of the company’s approach to whole person health.” Fitbit is a subsidiary of Alphabet Inc.’s Google. Dr. Vindell Washington, MD, CEO of Onduo, said:

 

“With a mission to help people get healthier, Fitbit helps users manage their holistic health and wellness, making them a perfect complement to our whole-person health promise. Together with Fitbit, we’ll be able to better support condition-specific management and our members' overall health and wellness by providing new tools and actionable guidance to support their health journeys. For example, in using Fitbit Onduo members will receive Fitbit insights like how increased activity can decrease resting heart rate — and they will be able to proactively engage in the management of their activity, sleep and nutrition.”

 

Earlier this year, Royal Philips (NYSE:PHG) advanced the case for wearable devices for cardiac conditions with its acquisition of remote cardiac diagnostics and monitoring firm BioTelemetry, Inc. A Philips spokesperson told Medical Device Network:

 

“The acquisition of BioTelemetry will add to [Philips’ portfolio of] leading cardiac diagnostics and monitoring solutions, comprised of wearable connected heart monitors, AI-based data analytics and services. These clinically validated solutions are focused on the diagnosis and monitoring of heart rhythm disorders.

 

BioTelemetry provides services for over one million patients per year and has built the world’s largest remote cardiac monitoring services network. Acquiring BioTelemetry will further broaden and scale our patient care management solutions for the hospital and the home to enhance patient outcomes, streamline clinical workflows and increase productivity.”

 

So while future research might indicate more clearly the impact of COVID-19 on the market, it is clear that demand for wearable medical devices is well established and growing regardless.

 

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors.  Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast ,  Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and  the AI Eye Podcast.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Disclosure: GTCHD is a monthly paid featured AI/tech stock on Investorideas.com Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

Get more Technology stock investor ideas - news, articles, podcasts and stock directories

New #Stocks to Watch -Biotech (NasdaqGS: $ERAS) (Nasdaq: $TCRX) (Nasdaq: $HCWB), Mining (CSE: $GMR.C) (CSE: $ATHA.C) Cannabis (CSE: $XBRA.C)

 New #Stocks to Watch -Biotech (NasdaqGS: $ERAS) (Nasdaq: $TCRX) (Nasdaq: $HCWB), Mining (CSE: $GMR.C) (CSE: $ATHA.C) Cannabis (CSE: $XBRA.C) 

 

Point Roberts WA, Delta BC, October 22, 2021 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Mining and Cannabis. Today’s stocks have been added to our lists of free stock directories in each sector.

 

Read this in full at https://www.investorideas.com/news/2021/main/10221Stocks.asp

 

The newest biotech companies are all recent Nasdaq IPOs focusing on cancer therapies, kidney disease, Alzheimer’s, diseases of the skin and infectious diseases.

 

The latest mining companies are all CSE-listed with operations in North America.

 

The newest cannabis company is an international cannabis company that includes infused beverages.

 

New Stocks added to Biotech Stocks Directory:

Erasca, Inc. (NasdaqGS:ERAS) At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

 

TScan Therapeutics, Inc. (Nasdaq:TCRX) is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

 

HCW Biologics Inc. (Nasdaq: HCWB) is a transformative immunotherapy company that focuses on inflammaging, a state of unresolved inflammatory responses and chronic inflammation. The Company is developing novel immunotherapies designed to improve health by disrupting the link between chronic, low-grade inflammation and age-related diseases such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases and autoimmune diseases. HCW uses its TOBI™ discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties for the treatment of inflammaging. Two of HCW Biologics lead inventions via TOBI™ include molecules HCW9218 and HCW9302, both currently undergoing IND-enabling studies.

 

Imago BioSciences, Inc. (Nasdaq: IMGO) is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF.

 

Unicycive Therapeutics, Inc. (Nasdaq: UNCY) is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

 

Transcode Therapeutics, Inc. (Nasdaq: RNAZ) is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company’s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.

 

Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer’s disease. Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational immunotherapy drug, ACU193, a humanized monoclonal antibody that selectively targets toxic AβOs in a Phase I clinical trial involving early Alzheimer’s disease patients.

 

Dermata Therapeutics, Inc. (Nasdaq:DRMA) is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. The Company's lead product candidate, DMT310, is the first product candidate being developed from its Spongilla technology platform. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 is currently under clinical development for the treatment of acne, psoriasis, and rosacea. Our second product candidate, DMT410, uses our Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of multiple aesthetic skin conditions. Dermata is headquartered in San Diego, California.

 

Eliem Therapeutics, Inc. (Nasdaq: ELYM) is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

 

Adagio Therapeutics, Inc. (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.

 

ABVC BIOPHARMA, INC. (Nasdaq: ABVC) is a clinical-stage biopharmaceutical company focused on development of therapeutic solutions in oncology/hematology, the central nervous system (CNS), ophthalmology, and medical devices related to these fields. Its current pipeline features six drugs and a medical device, ABV-1701/Vitargus®. For its drug products, it is focused on conducting proof-of-concept trials through Phase II of clinical development at world-famous research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the company intends to conduct clinical trials through Phase III at various locations throughout the world.

 

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Tyra is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. Tyra is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Tyra's lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer.

 

DICE Therapeutics, Inc. (Nasdaq: DICE) is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

 

New stocks added to Mining Stocks Directory:

Brascan Gold Inc. (CSE: BRAS) is a gold exploration issuer based in Vancouver, BC. The Company holds an option over the Vulcan Property, located in the Fort Steele Mining Division in southeastern BC.

 

Gelum Resources Ltd. (CSE: GMR) is a company focused on mineral exploration in British Columbia. Its principal project is the Eldorado Gold Property located in the Bralorne-Bridge River Gold district in south-central British Columbia.

 

Athena Gold Corporation (CSE: ATHA) is engaged in the business of mineral exploration and the acquisition of mineral property assets. Its objective is to locate and develop economic precious and base metal properties of merit and to conduct its exploration program on the Excelsior Springs Project, located in Esmeralda County, Nevada, approximately 45 miles southwest of Goldfield, Nevada.

 

New Stocks added to Cannabis Stocks Directory:

Xebra Brands Ltd. (CSE: XBRA) is an international cannabis cultivation and product company with global brands and intellectual property. Xebra’s products range from wellness to leisure, and include beverages.

 

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

 

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors.  Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast ,  Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and  the AI Eye Podcast.

 

Learn about investing in stocks and sector trends with our news alerts, articles,  podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.

 

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.  

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android  

 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Breaking #AI #Health #Stock News: GBT (OTCPK: $GTCH) Roadmaps the Development of a #Wearable Version for its qTerm Device; #ArtificialIntelligence

 Breaking #AI #Health #Stock News: GBT (OTCPK: $GTCH) Roadmaps the Development of a #Wearable Version for its qTerm Device; #ArtificialIntelligence

 

The wearable version is planned to include the same features as the finger-touch device including intelligent #health monitoring and alert capabilities

 

San Diego, CA, October 20, 2021 - (Investorideas.com Newswire) GBT Technologies Inc. (OTC PINK: GTCH) ("GBT” or the “Company”) has on its roadmap, a wearable version of the qTerm device. The finger-touch version prototype of the device is now under manufacturing; and the company plans to start a wearable version next year. GBT's qTerm, a human vitals device, is aimed to measure human vitals with the touch of a finger.

 

Read this in full at https://www.investorideas.com/CO/GOPH/news/2021/10201Wearable-qTerm-Device.asp

 

According to Gartner’s (Gartner Forecasts Global Spending on Wearable Devices to Total $81.5 Billion in 2021) forecast, the world will spend about $81.5 billion on wearable devices in 2021, a significant rise compared to 2020. This rise is directly correlated with the global pandemic and the importance of health monitoring in our lives.

 

The qTerm wearable device is planned to have all features of the finger-touch version plus additional features that can be utilized due to its shape characteristics. Upon a user’s permission; an automatic scheduled monitoring feature is planned for on-going health observation. The device’s AI system will learn about the user’s health concerns and conditions, and perform health checks as part of a daily routine, transparent to the user. Even if users forget to take vitals measurements, the device will do it automatically for them. Based on the device’s cognitive and reasoning capabilities, automatic vitals measurements will be taken continuously throughout the day. In case of abnormal results, the device will alert, and advice on further steps; the device can be integrated with clinics and hospital data systems to keep and monitor patient’s records. It will be able to directly alert physicians about any health-related concerns and could also be used during telemedicine sessions. The wearable device plans to use optical sensors technology with an advanced display. Additionally, a web portal synchronized with a mobile application is planned to support qTerm’s wearable version. And just like the finger-touch version, the data will be securely kept and transferred to a back-end AI program for further analysis and monitoring. Due to the device’s nature, GBT will continue evaluating the addition of more wearable-oriented features to increase its added value. GBT plans to start the device’s design in early 2022.     

 

"It is only natural to create a wearable version of qTerm technology. One of the major advantages of a wearable form of qTerm is its capabilities to take health related measurements; independently, and without the user’s awareness, this feature can be enabled upon the user’s permission. We see this feature as a great advantage; especially, when users may forget to take their scheduled vitals, not aware of a potential problem. The wearable version of qTerm will be equipped with the same AI system for on-going health monitoring, and it will learn about a user’s health condition and perform scheduled checks to ensure good health. These checks will be executed throughout the day or night and in case of abnormalities the user will be alerted, and can be an efficient health monitoring system for the elderly; 24/7. In qTerm’s finger-touch version the responsibility to perform a vitals check lies on the user remembering to take these on time. However, with the wearable device the checks will be automatically executed throughout the day in case the user forgets their daily health-related duties, this system will do it for them. qTerm wearable will include a website synchronized mobile application for results representation. This advanced mobile application will make the qTerm wearable device a personal health monitoring system constantly on the watch, checking, analyzing and advising/alerting about any health concerns," said Danny Rittman the Company’s CTO.

 

There is no guarantee that the Company will be successful in researching, developing or implementing this system.  In order to successfully implement this concept, the Company will need to raise adequate capital to support its research and, if successfully researched, developed, the Company would need to enter into a strategic relationship with a third party that has experience in manufacturing, selling and distributing this product.  There is no guarantee that the Company will be successful in any or all of these critical steps. 

 

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
press@gopherprotocol.com

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

  Get more tech stocks investor ideas- news, articles, podcasts and stock directories

 

 

 

Breaking #AI #Stock News: GBT (OTCPK: $GTCH) Develops an iOS Mobile Application For its qTerm Device, Synchronized With its Website; #Artificialintelligence

 Breaking #AI #Stock News: GBT (OTCPK: $GTCH) Develops an iOS Mobile Application For its qTerm Device, Synchronized With its Website; #Artificialintelligence

 

The mobile app is planned to communicate with GBT's #AI engine for intelligent #health monitoring and alert capabilities

 

San Diego, CA - October 12, 2021 (Investorideas.com Newswire) GBT Technologies Inc. (OTC PINK: GTCH) ("GBT" or the "Company") is developing an iOS (iPhone version) mobile application for its qTerm device. The iOS application will be synchronized with qTerm's website and Widget. The mobile app will establish Low Energy Bluetooth (BLE) with the device electronics and show the user vitals results upon taking measurements. A secured infrastructure for user's privacy and confidentiality will be prepared following industry cybersecurity standards.

 

Read this news, featuring GTCH in full at https://www.investorideas.com/CO/GOPH/news/2021/10121iOS-Mobile-Application-qTerm.asp

 

The application will be targeted to provide all necessary data to be transferred to an AI engine for further processing. GBT's qTerm, a human vitals device, is aimed to measure human vitals with a touch of a finger. The iOS mobile application is planned to provide real-time visual results, and at a later stage will include AI statistics and analysis. An Android version was already developed a few months ago and was used during prototype testing.

 

GBT plans to develop a dedicated version of its Avant! AI system to perform user's on going vitals monitoring and analytics. The system is designed to alert in case of abnormal results, remind about medial check/follow-ups, and monitor medications. Upon taking vitals measurement, the iPhone app will present the data, with full synchronization with qTerm's web portal, including body temperature color code visual feedback for immediate abnormality identification. The web application Widget will be supporting the iOS version to enable remote telemedicine possibilities. GBT will evaluate adding to the app vital health related information like close by clinics, urgent care sites and hospital locations. An initial version of the iOS mobile app is targeted to be complete by the end of the year.

 

"Mobility is a key feature with today's technology and qTerm is no different. We are currently building an iOS mobile application to enable results review and AI communication channel. The mobile app is based on the user's interface of the qTerm's device, ensuring Bluetooth connection with its electronics, and at a later stage, communicating the information with its AI system for further analysis. The iPhone mobile application will be synchronized with the device's website and Widget. An Android version was already developed and was used for prototype testing, the iOS version will be parallel to support iPhone devices. The app will present vitals measurement, including rapid color-code visual feedback for abnormal results. Users will be able to access their data via the mobile app and personal computer using the web application; worldwide. The data will be secured with the most up-to-date cybersecurity measures to keep user's privacy and confidentiality. The company will consider adding additional important health related information like, nearest clinics, urgent care sites, and hospital locations. A robust mobile technology for iPhones and Android devices is a key feature of the qTerm device and we plan to further develop its capabilities. Utilizing modern iOS mobile technology, will make the qTerm device a global, personal, health assistant; to monitor, analyze, advise and alert, keeping our lives healthier and happier," said Danny Rittman, the Company's CTO.

 

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) ("GBT") (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT's mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT's goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT's vision is to produce this system as a low cost, secure, private-mesh-network between all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

 

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
press@gopherprotocol.com

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

  Get more tech stocks investor ideas- news, articles, podcasts and stock directories

 

Breaking #AI #Health #Stock News: GBT (OTCPK: $GTCH) is Enhancing its Avant! AI #Technology to Support #Healthcare Advisory System; #artificialintelligence

 Breaking #AI #Health #Stock News: GBT (OTCPK: $GTCH) is Enhancing its Avant! AI #Technology to Support #Healthcare Advisory System; #artificialintelligence  

 

Improving overall Avant! mobile and web user’s experience, and connecting it with health-related data resources!  

 

San Diego, CA, October 7, 2021 - (Investorideas.com Newswire) GBT Technologies Inc. (OTC PINK: GTCH) ("GBT”, or the “Company”), is enhancing its Avant! AI technology, while enabling a healthcare advisory system. The company is in the process of an enhancement phase to improve Avant! back-end architecture, supporting better imaging and user interface. Advanced image recognition techniques are planned for implementation combined with efficient memory handling to enable faster performance.

 

Read this news featuring GTCH in full at https://www.investorideas.com/CO/GOPH/news/2021/10071Avant-Healthcare-Advisory-System.asp

 

Avant! dialog interface is being enhanced, enabling robust Q/A possibilities combined with easier user interactions. Avant! will be trained with health-related information and con-nected with accredited data resources, enabling a generalized health advisory system; and will consider a domain-specific later. Avant! AI belongs to an emerging generation of chat-based artificial intelligence applications that enable a user’s conversation through a chat dialog interface, allowing it to understand and respond to questions and natural language inputs.

 

GBT is developing the system to address the needs of a new era of intelligent telemedicine, one that will assist patients and healthcare specialists through connected devices. Its AI-driven solutions aim to benefit users, while addressing the unique challenges of the fastest growing healthcare segment. These intelligent advisory capabilities target to effectively provide reliable, first line, real-time, health related advice worldwide. Avant! enhancement phase targets completion during the next few months, after which we will release a new version of both mobile and web applications.

 

“Avant! AI is capable of being an efficient data-driven information agent; currently, it’s released as an AGI (Artificial General Intelligence) agent and we have decided to focus on a more specific field. Naturally, due to the world’s health crisis special attention will be given to the health domain, and we are going to enable Avant! to become a knowledge-based health advisory system. It will be connected to credible health-related resources set to respond to general health related questions. We are implementing a series of enhancements to handle big-data with better understanding of the user’s question capabilities, users will be able to get first-line, relevant advice; 24/7. Avant! health agent will also be aimed as an assisting tool for healthcare professionals; especially, assisting remote locations. Additionally, we are enhancing the user interface to improve the human-to-computer experience, making it more user friendly; mainly intuitive. GBT uses artificial intelligence solutions to create health assistance and monitoring value; particularly, in this new era of telemedicine. Our AI technology can also become an innovative foundation of the future patient-clinic experience, changing the way our world practices medicine,” said Danny Rittman the Company’s CTO.

 

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

 

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
press@gopherprotocol.com

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

  Get more tech stocks investor ideas- news, articles, podcasts and stock directories